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analyzed the TERT promoter by direct sequencing and 
genotyping in 466 medulloblastomas. The mutational dis-
tributions were determined according to subgroup affilia-
tion, demographics, and clinical, prognostic, and molecu-
lar features. Integrated genomics approaches were used 
to identify specific somatic copy number alterations in 
TERT promoter-mutated and wild-type tumors. Over-
all, TERT promoter mutations were identified in 21 % of 
medulloblastomas. Strikingly, the highest frequencies of 
Abstract Telomerase reverse transcriptase (TERT) 
promoter mutations were recently shown to drive telom-
erase activity in various cancer types, including medul-
loblastoma. However, the clinical and biological impli-
cations of TERT mutations in medulloblastoma have not 
been described. Hence, we sought to describe these muta-
tions and their impact in a subgroup-specific manner. We 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-013-1198-2) contains supplementary 
material, which is available to authorized users.
M. remke · V. ramaswamy · J. Peacock · D. J. H. Shih · N. Hill · 
F. M. g. Cavalli · X. Wang · S. C. Mack · M. Barszczyk · 
A. S. Morrissy · X. Wu · S. Agnihotri · B. luu · l. garzia · 
A. M. Dubuc · N. Zhukova · r. Vanner · M. D. Taylor 
The Arthur and Sonia labatt Brain Tumour research Centre,  
The Hospital for Sick Children, Toronto, ON, Canada
M. remke · V. ramaswamy · J. Peacock · D. J. H. Shih · N. Hill · 
F. M. g. Cavalli · X. Wang · S. C. Mack · A. S. Morrissy · X. Wu · 
B. luu · l. garzia · A. M. Dubuc · M. D. Taylor 
Developmental and Stem Cell Biology Program,  
The Hospital for Sick Children,  
Toronto, ON, Canada
M. remke · V. ramaswamy · J. Peacock · D. J. H. Shih · 
X. Wang · S. C. Mack · A. M. Dubuc · S. e. Croul · 
M. D. Taylor (*) 
Department of laboratory Medicine and Pathobiology, 
University of Toronto, Toronto, ON, Canada
e-mail: mdtaylor@sickkids.ca
C. Koelsche · A. Korshunov · A. von Deimling (*) 
Department of Neuropathology, University Hospital Heidelberg, 
Heidelberg, germany
e-mail: andreas.vondeimling@med.uni-heidelberg.de
C. Koelsche · A. Korshunov · A. von Deimling 
Clinical Cooperation Unit Neuropathology, german Cancer 
research Center (DKFZ), Heidelberg, germany
P. A. Northcott · M. Kool · D. T. W. Jones · S. M. Pfister 
Division of Pediatric Neurooncology, german Cancer research 
Center (DKFZ), Heidelberg, germany
J. M. Kros 
Department of Pathology, erasmus Medical Center, rotterdam, 
The Netherlands
P. J. French 
Department of Neurology, erasmus Medical Center, rotterdam, 
The Netherlands
918 Acta Neuropathol (2013) 126:917–929
1 3
TERT mutations were observed in SHH (83 %; 55/66) and 
WNT (31 %; 4/13) medulloblastomas derived from adult 
patients. group 3 and group 4 harbored this alteration in 
<5 % of cases and showed no association with increased 
patient age. The prognostic implications of these mutations 
were highly subgroup-specific. TERT mutations identified 
a subset with good and poor prognosis in SHH and group 
4 tumors, respectively. Monosomy 6 was mostly restricted 
to WNT tumors without TERT mutations. Hallmark SHH 
focal copy number aberrations and chromosome 10q dele-
tion were mutually exclusive with TERT mutations within 
SHH tumors. TERT promoter mutations are the most com-
mon recurrent somatic point mutation in medulloblas-
toma, and are very highly enriched in adult SHH and WNT 
tumors. TERT mutations define a subset of SHH medul-
loblastoma with distinct demographics, cytogenetics, and 
outcomes.
Keywords TerT promoter mutations · SHH pathway · 
Adult · Medulloblastoma
Introduction
Medulloblastoma is a highly malignant embryonal brain 
tumor located in the posterior fossa [6, 29, 33, 35]. While 
this tumor comprises the most common malignant brain 
tumor in children, it only accounts for approximately 
1 % of primary CNS tumors in adults [18, 20]. The cur-
rent consensus recognizes four core molecular subgroups 
(WNT, SHH, group 3, and group 4) with distinct molecu-
lar, demographic, clinicopathological, and prognostic char-
acteristics [5, 15, 16, 26, 27, 37, 38, 41, 42]. The defining 
features of medulloblastoma subgroups differ dramatically 
according to age at diagnosis [15, 27, 41]. Specifically, 
group 3 tumors are largely confined to non-adults, SHH 
tumors are most frequent in infants and adults, while WNT 
and group 4 medulloblastomas are mostly observed in 
pediatric cohorts [15, 24, 27, 38, 41]. Particularly within 
SHH tumors, age-associated heterogeneity was observed 
regarding the transcriptional characteristics, somatic copy 
number alterations (SCNA), and the prognostic impli-
cations of biomarkers [15, 18, 38, 40]. Delineation of 
tumorigenic features characteristic for these age-related 
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differences, particularly within SHH tumors, are highly 
desirable to understand these clear biological and prognos-
tic discrepancies.
Telomere maintenance is fundamentally important to 
normal self-renewing stem cells and cancer cells [3, 7, 9, 
14, 22]. It has been suggested that tumors derived from cell 
populations with low self-renewal capacity generally rely 
on alterations that restore telomerase activity, while epi-
genetic mechanisms maintain telomerase activity in tumor 
types derived from self-renewing stem cells [13]. The iden-
tification of recurrent telomerase reverse transcriptase 
(TERT) promoter mutations in 21 % of 91 medulloblasto-
mas [13] is intriguing, since other mechanisms converg-
ing on increased telomerase activity including alternative 
lengthening of telomeres (AlT) [8] or mutations affect-
ing the ATRX/DAXX complex are excessively uncommon 
in medulloblastoma [12, 25, 32, 34, 39]. Although TERT 
mutations have been reported in several cancers [2, 10, 11, 
13, 19, 43], their putative association with distinct biologi-
cal behavior and clinical or even prognostic characteristics 
has not been comprehensively studied. The initial analyses 
of TERT mutations in medulloblastoma [12] mainly cata-
logued the mutational frequency rather than correlating the 
molecular and clinical features of these mutations in a sub-
group-specific manner.
In this study, we analyzed a representative set of 466 
medulloblastomas for TERT promoter mutations. Sub-
sequently, we correlated the mutational distribution with 
clinicopathological features, outcome, and molecular char-
acteristics in a subgroup-specific manner. We demonstrate 
that TERT promoter mutations comprise the most recurrent 
mutation in adult SHH tumors identified to date and poten-
tially define distinct prognostic subgroups in SHH and 
group 4 medulloblastoma patients.
Materials and methods
Tumor material and patient characteristics
All tissues and clinicopathological information were seri-
ally collected in accordance with institutional review boards 
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from various contributing centers to this study. Nucleic acid 
extractions were carried out as previously described [28]. 
The clinicopathological characteristics of the investigated 
patient cohort are outlined in Table 1. The median follow-
up was 44.06 months (range 0.7–301.5 months).
gene expression and copy number analysis
Subgroup affiliation was determined using nanoString 
limited gene expression profiling as previously described 
[31]. Somatic copy number alterations were assessed on 
the Affymetrix Single Nucleotide Polymorphism (SNP) 
6.0 array platform in 418 of 466 cases to identify SCNAs 
specific for TERT mutant and wild-type tumors. raw 
copy number estimates were obtained in dChip, followed 
by CBS segmentation in r as previously described [30]. 
Somatic copy number alterations were identified using 
gISTIC2 [21]. TERT expression levels were compared 
using r2 (www.r2.amc.nl). Differences in expression were 
tested using one-way ANOVA.
Sanger sequencing
Isolated DNA (25 ng) from all 466 tumors and 7 matched 
germline samples (25 ng) was amplified by PCr. PCrs 
contained 1 μl DNA template, 10 μM forward (5′-CAg 
ggC ACg CAC ACC Ag-3′) and reverse (5′-gTC CTg 
CCC CTT CAC CTT C-3′) TerT-specific primers, and 
12.5 μl HotStar Taq Plus Master Mix (Qiagen, gaith-
ersburg, Maryland, USA) in a 25 μl total reaction vol-
ume. Cycle parameters comprised 95 °C × 15 min; 28 
cycles of 98 °C × 40 s, 65 °C × 30 s, 72 °C × 1 min; 
72 °C × 10 min. PCrs were carried out using the C1000 
Thermal Cycler (Biorad, Hercules, CA, USA). PCr prod-
ucts were purified with the Purelink PCr Micro kit (life 
Technologies, Burlington, ON, Canada). In all experiments, 
controls were included in the absence of DNA to rule out 
contamination by PCr products. Templates for Sanger 
sequencing were analyzed with forward (5′-CAg CgC 
TgC CTg AAA CTC-3′) and reverse (5′-gTC CTg CCC 
CTT CAC CTT C-3′) sequencing primers using dgTP Big-
Dye Terminator v3.0 Cycle Sequencing ready reaction Kit 
(life Technologies), and 5 % DMSO on the ABI3730Xl 
capillary genetic analyzer (life Technologies).
genotyping assay
Two primers (forward primer, 5′-CAg CgC TgC CTg 
AAA CTC-3′; reverse primer, 5′-gTC CTg CCC CTT 
CAC CTT C-3′) were designed to amplify a 163-bp prod-
uct encompassing C228T and C250T hotspot mutations 
in the TERT promoter—corresponding to the positions 
124 and 146 bp, respectively, upstream of the ATg start 
site. Two fluorogenic lNA probes were designed with 
different fluorescent dyes to allow single-tube genotyp-
ing. One probe was targeted to the WT sequence (TERT 
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WT, 5′-5HeX-CCC CTC CCg g-3IABkFQ-3′), and one 
was targeted to either of the two mutations (TERT mut, 
5′-56FAM-CCC CTT CCg g-3IABkFQ). Primer and 
probes were custom designed by Integrated DNA Technol-
ogies (Coralville, Iowa, USA) using internal SNP design 
software, and sequence homogeneity was confirmed by 
comparison to all available sequences on the genBank 
database using BlAST (http://www.ncbi.nlm.nih.gov/
BlAST/). Primers were optimized to avoid for hairpins and 
homo- and heterodimers. Primers and probes were obtained 
from Integrated DNA Technologies.
real-time PCr was performed in 25 μl reaction mix-
tures containing 12.5 μl of TaqMan Universal Master Mix 
II with UNg (Applied Biosystems), 900 nM concentrations 
of each primer, 250 nM TERT WT probe, 250 nM TERT 
MUT probe, and 1 μl (25 ng) of sample DNA. Thermocy-
cling was performed on the StepOnePlus (Applied Biosys-
tems) and consisted of 2 min at 50 °C, 10 min at 95 °C, and 
40 cycles of 95 °C for 15 s and 60 °C for 1 min.
Analysis was performed using StepOne Software, ver-
sion 2.1. Samples were considered mutant if they had CT 
values of ≤39 cycles. each sample was verified visually by 
examining the PCr curves generated to eliminate false pos-
itives due to aberrant light emission. end-point allelic dis-
crimination genotyping was performed by visually inspect-
ing a plot of the fluorescence from the WT probe versus 
the MUT probe generated from the post-PCr fluorescence 
read.
Statistical analysis
Survival time according to TERT mutational status was 
assessed using the Kaplan–Meier estimate and a log-rank 
test. Comparisons of binary and categorical patient char-
acteristics between subgroups and cohorts were performed 
using the two-sided Fisher’s exact test or Chi-squared test. 
Continuous variables were analyzed using the Mann–Whit-
ney U test. p values <0.05 were considered statistically sig-
nificant. Multivariate Cox proportional hazards regression 
was used to adjust for additional covariates using the sur-
vival r package (v.2.36). All other statistical analyses were 
performed using StataSe 12 (Stata Corp. College Station, 
TX, USA) and graphpad Prism 5 (la Jolla, CA, USA).
Results
Characteristics of TERT-mutated medulloblastomas
We performed Sanger sequencing on a clinically well-
annotated medulloblastoma cohort (n = 466), reflecting 
the spectrum of demographics and histological subtypes 
of the disease (Table 1; Supplementary Figure 1A). Our 
results were verified using a Taqman-based genotyping 
assay that detects both of the most highly recurrent TERT 
promoter mutations (C228T and C250T). Since both 
mutational hotspots are located in highly homologous 
sequences, C228T and C250T mutations result in an iden-
tical binding sequence for the mutation-specific probe 
(CCCggAAgggg; Supplementary Figure 1B). A total 
of 21 % of medulloblastomas harbored TERT mutations 
(Fig. 1a). In line with a previous report, these mutations were 
enriched in older patients (Table 1; p < 0.0001), all muta-
tions were heterozygous, and none of the available matched 
germline controls displayed this mutation [13]. Interestingly, 
we found that TERT-mutated medulloblastomas present less 
Table 1  Clinicopathological and molecular characteristics according 
to TERT mutational status
F female, LC/A large cell/anaplastic, M male, MB medulloblastomal, 
MBEN medulloblastoma with extensive nodularity, NA not available 
(data were excluded from statistical comparison)
Bold values indicate p < 0.05
#
 Mann–Whitney U test
Φ
 Fisher’s exact test
χ
 Chi-square test
Characteristic TERT MUT TERT WT p value
Age (years)
 Median 22.00 7.08 <0.0001#
 range 0.66–49.00 0.24–56.32
 NA 1 0
gender
 Male 56 236 0.47Φ
 Female 37 129
 NA 3 5
Histology
 MBeN 3 8 0.59χ
 Desmoplastic 10 59
 Classic 46 217
 lC/A 11 38
 NA 26 48
M-stage
 M0 58 240 0.03Φ
 M1-3 12 103
 NA 26 27
TP53 status
 MUT 4 12 0.78Φ
 WT 42 97
 NA 50 261
Subgroup
 WNT 6 47 <0.0001χ
 SHH 80 133
 group 3 2 48
 group 4 8 142
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frequently with metastatic dissemination at diagnosis com-
pared to TERT wild-type tumors (p = 0.03).
TERT mutations are specifically enriched in SHH 
medulloblastomas
In a subgroup-specific analysis, we revealed that TERT 
mutations were significantly enriched in SHH tumors 
(80/213; 38 %; p < 0.0001) compared to WNT (6/53; 11 %) 
and group 3 (2/50; 4 %) or group 4 tumors (8/150; 5 %). 
TERT mutations in both WNT and SHH medulloblasto-
mas were positively correlated with age. TERT mutations 
were significantly enriched in adult patients (Fig. 1c, d, 
both p < 0.0001). Increasing age was not associated with 
increased mutational frequency in either group 3 or group 
4 tumors (n.s.). While histopathological features were simi-
lar between TERT-mutated and wild-type tumors across 
subgroups, we observed that classic histology was more 
commonly observed in TERT mutant SHH tumors, and 
desmoplastic histology in wild-type SHH tumors (Fig. 1e; 
Table 2; p = 0.04), respectively.
Prognostic implications of TERT mutations
When medulloblastoma patients across all subgroups 
were stratified by TERT mutational status, we observed 
no significant differences in survival (Fig. 2a; p = 0.45). 
Further after normalizing the subgroup composition to 
reported subgroup ratios, a statistical difference was still 
not revealed (data not shown; p = 0.36) [1, 15, 26, 41]. 
However, when TERT mutational status is re-analyzed in a 
subgroup-specific manner, several important survival asso-
ciations are observed. TERT mutations had no prognostic 
impact within WNT tumors (Fig. 2b; p = 0.17). However, 
a significant association between TERT promoter mutations 
and outcomes was noted in SHH and group 4 medullo-
blastomas. Specifically, the 5-year overall survival of SHH 
tumors with and without TERT mutations was 77.6 ± 7 % 
Fig. 1  TERT promoter-mutated 
medulloblastomas display dis-
tinct demographics, histology, 
and subgroup affiliation. a Bar 
graph indicating the frequency 
of TERT mutations in 466 
primary medulloblastomas. b 
Prevalence of TERT mutations 
according to medulloblastoma 
subgroups, and within, c WNT 
and d SHH subgroups accord-
ing to age groups. Distribution 
of histological variants within 
SHH tumors according to TERT 
mutational status (e). MUT 
mutation, OS overall survival, 
WT wild-type
a b
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and 64.1 ± 5.1 %, respectively (Fig. 2c; p = 0.04). In 
contrast to the improved prognosis of TERT mutant 
SHH tumors, we observed the inverse pattern in group 4 
tumors where the 5-year overall survival for patients with-
out and with TERT mutations was 73.3 % ± 4.3 % and 
62.5 % ± 17.1 % (Fig. 2d; p = 0.04). Similar to the unfa-
vorable prognosis of TERT mutations in group 4 tumors, 
both of the patients with TERT-mutated group 3 tumors 
died after 7 and 45 months of follow-up, respectively (Sup-
plementary Table 1). Thus, we conclude that TERT muta-
tions define distinct prognostic patient cohorts in a sub-
group-specific fashion with good prognosis in SHH and 
poor prognosis in group 4 medulloblastomas.
Survival analysis restricted to specific age groups
As TERT mutations are predominantly observed in non-
infant medulloblastomas, we evaluated the prognostic 
implications of these promoter mutations across all four 
medulloblastoma subgroups in an age-dependent manner. 
TERT mutational status across subgroups had no prog-
nostic impact among patients older than 3 years of age at 
diagnosis (Fig. 3a; p = 0.59). Interestingly, the prognos-
tic impact of TERT mutation was more pronounced in the 
non-infant SHH population with a 5-year overall survival 
of 76.9 % ± 7.6 % and 59.3 % ± 6.9 % of non-infants 
with and without TERT promoter mutations, respectively 
(Fig. 3b; p = 0.019). These prognostic implications were 
similar in adult medulloblastoma patients and in the adult 
SHH subgroup (Supplementary Figure 2). In a subset of 
76 SHH cases with known TP53 mutational status [44], 
we revealed that TP53 mutations identify non-infant SHH 
tumors with a particularly poor prognosis, while in con-
trast TERT mutations identify a subsets with good prog-
nosis (Fig. 3c; p = 0.047). Mutations of both TERT and 
TP53 were observed in 4/12 SHH tumors (Supplementary 
Table 2). Non-infant group 4 showed an inverse prognos-
tic association with poor outcome of TERT-mutated cases 
(Fig. 3d; p = 0.024). lastly, we analyzed the overall sur-
vival of SHH patients under a multivariate Cox propor-
tional hazards model comprising age at diagnosis, TERT 
mutational status, M-stage, and histology. In addition to the 
known prognostic significance of M-stage (p < 0.001) and 
histology (p = 0.02), we revealed that TERT status con-
tinued to be associated with good prognosis (Hr 0.17, CI 
0.04–0.69, p = 0.01), independent of other prognostic fac-
tors including age at diagnosis (p = 0.35).
Distinct somatic copy number alterations of TERT-mutated 
medulloblastomas
To identify additional genetic features associated with these 
distinct demographic and clinical differences, we evaluated 
broad and focal copy number alterations according to sub-
group affiliation and TERT promoter mutations. Notably, 
only 1/6 (17 %) of TERT-mutated WNT tumors harbored 
monosomy 6, while this alteration is observed in approxi-
mately 80 % of TERT wild-type medulloblastomas of the 
WNT subgroup (Fig. 4a; p = 0.005). loss of chromo-
some 2 and 10q loss were significantly enriched in TERT 
wild-type SHH tumors, while 3q loss was more frequently 
observed in their TERT mutant counterparts (Fig. 4b). Pre-
viously described focal alterations characteristic for SHH 
tumors including amplification of MYCN/GLI2/CDK6/
YAP1/PPM1D, and deletions targeting PTCH1/CDKN2A/
CDKN2B/PTEN were largely confined to TERT wild-type 
SHH medulloblastomas, while TERT mutant SHH (Fig. 5) 
and group 4 (Supplementary Figure 3) showed very few 
focal SCNAs. Consistent with the higher frequency of 
TERT mutations in SHH tumors, we observed increased 
TERT expression in the SHH subgroup compared to group 
Table 2  Clinicopathological and molecular characteristics of SHH 
medulloblastoma according to TERT mutational status
F female, LC/A large cell/anaplastic, M male, MB medulloblastoma, 
MBEN medulloblastoma with extensive nodularity, NA not available 
(data were excluded from statistical comparison)
Bold values indicate p < 0.05
#
 Mann–Whitney U test
Φ
 Fisher’s exact test
χ
 Chi-square test
Characteristic TERT MUT TERT WT p value
Age (years)
 Median 25.00 3.00 <0.0001#
 range 0.66–49.00 0.24–52.00
 NA 1 0
gender
 Male 46 80 0.77Φ
 Female 31 48
 NA 3 5
Histology
 MBeN 3 4 0.04χ
 Desmoplastic 10 44
 Classic 34 47
 lC/A 10 16
 NA 23 22
M-stage
 M0 46 87 0.84Φ
 M1-3 10 22
 NA 24 24
TP53 status
 MUT 4 8 1Φ
 WT 38 71
 NA 38 54
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4 tumors in two independent gene expression profiling 
studies (p < 0.001; Supplementary Figure 4). Furthermore, 
we observed TERT amplification in two tumors included in 
the entire cohort of 1,088 previously studied tumors [30]. 
Both of these cases with TERT amplification were SHH-
driven medulloblastomas with wild-type TERT status, 
which were derived from pediatric patients who were both 
alive after 15 and 83 months of follow-up (Supplementary 
Figure 5). Thus, broad and focal SCNAs underline that 
TERT mutations define a genetically distinct subset within 
SHH tumors and possibly within the WNT and group 4 
tumors.
Discussion
The underlying biology of adult medulloblastomas remains 
poorly understood. Next-generation sequencing stud-
ies have revealed a broad spectrum of novel, potentially 
tumorigenic mutations in the recent past, but none of these 
studies focused on adult medulloblastomas [12, 25, 32, 34, 
39]. In addition, the vast majority of these mutations are 
not recurrent enough to stratify patients into distinct clini-
cal and prognostic subgroups.
In this study, we demonstrate that TERT promoter muta-
tions, initially described in melanoma [10, 11], comprise 
the most recurrent mutation described so far across medul-
loblastoma subgroups, with a particular enrichment in 
older patient cohorts. These somatic mutations are espe-
cially common in older patients with SHH tumors (83 %) 
and to a lesser extent in adults with WNT medulloblasto-
mas (11 %). Based on the transcriptional heterogeneity of 
SHH tumors in infant and adult patients, we suspect that 
the adult cluster mainly comprised TERT-mutated medul-
loblastomas [24]. According to the initial classification of 
tumor types with TERT mutations at frequencies over 15 % 
(TERT-high) vs. below this threshold (TERT-low) [13], our 
report suggests distinct baseline telomerase activity of the 
cell of origin in each of the subgroups (group 3 ≥ group 
4 > WNT >> SHH). Furthermore, the identification of 
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Fig. 2  Prognostic impact of TERT promoter mutations varies accord-
ing to medulloblastoma subgroups. Kaplan–Meier estimate display-
ing overall survival (OS) according to TERT mutational status in pri-
mary medulloblastomas (a), within WNT (b), SHH (c), and group 4 
(d) subgroups. Survival differences were calculated using continuous 
log-rank tests. MUT mutation, OS overall survival, WT wild-type
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recurrent TERT promoter mutations makes a compelling 
argument that the increasing availability of whole-genome 
sequencing results may substantially add to a refined under-
standing of the mutational landscape of different biological 
and age-driven medulloblastoma subgroups, since earlier 
next-generation sequencing studies focusing on the pro-
tein-coding regions had not encompassed gene-regulatory 
regions including promoter mutations.
In this study, we demonstrate that the mutational status 
of the TERT promoter can segregate individuals with SHH 
a
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across subgroups (a), in SHH tumors (b), in SHH tumors (TP53 
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calculated using continuous log-rank tests
Fig. 4  WNT and SHH medul-
loblastoma harbor distinct 
broad genomic imbalances 
depending on the mutational 
status of TERT. Bar graphs 
indicating the frequency of 
broad cytogenetic alterations in 
WNT (a), and SHH (b) tumors. 
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and group 4 medulloblastomas with distinct prognostic 
outcomes, while a prognostic impact of this mutation was 
not observed in glioblastomas [23]. Molecular mecha-
nisms converging on TERT up-regulation were recently 
reported to be associated with dismal prognosis in pediat-
ric brain cancers [4]. Our findings in group 4 tumors with 
TERT mutations follow this pattern, while SHH tumors 
with TERT mutations comprise a prognostically favorable 
subgroup. Notably, survival curves of SHH tumors increas-
ingly approximate with extended follow-up. We hypoth-
esize that this pattern might be due to secondary malignan-
cies and late relapses in older SHH tumors [36–38]. Since 
virtually all of the TERT promoter mutations encompass 
the mutational hotspots C228T and C250T, patient strati-
fication can be carried out using a single PCr followed 
up with Sanger sequencing or with a single experiment 
using our newly designed Taqman-based genotyping assay. 
The latter assay is particularly suitable for routine clini-
cal applications as it is highly sensitive and specific (5 ng 
DNA input is sufficient). Furthermore, our Taqman-based 
genotyping assay can be used on DNA derived from fresh-
frozen and formalin-fixed paraffin-embedded tissue, since 
it only amplifies a short DNA fragment.
Both hotspot mutations C228T and C250T create an 
e-twenty-six (eTS) binding motif [10, 11] resulting in 
up-regulation of TERT expression at the mrNA level [2], 
which was not observed at the protein level in glioblas-
tomas [43]. We now demonstrate that SHH tumors with 
TERT mutations are mostly mutually exclusive with those 
harboring 10q loss (p = 0.017) Notably, the relatively 
favorable prognosis of TERT-mutated SHH medulloblas-
tomas may be explained by the relative lack of high-risk 
biomarkers [17, 18, 24, 44].
In summary, we describe the demographic, clinico-
pathological, and biological implications of TERT pro-
moter mutations in a subgroup-specific fashion. This study 
underlines the dependence of adult WNT and SHH tumors 
to reacquire telomerase activity and suggests a potential 
prognostic utility of TERT mutational analysis in an era of 
individualized therapy.
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